The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism.

Harsløf T, Sikjær T, Sørensen L, Pedersen SB, Mosekilde L, Langdahl BL, Rejnmark L

The Journal of clinical endocrinology and metabolism8 May 2015Cited by 18 (Europe PMC)

PMID25955226DOI10.1210/jc.2015-1477PepBankPUB-25955226

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, ucOC increased 1185.0 ± 814.4% with PTH versus 69.3 ± 79.4% with placebo (P < 10(-50)).
In plain wordsIn hypoparathyroidism, PTH increased undercarboxylated osteocalcin more than placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseUndercarboxylated osteocalcin
Study
n = 58
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg/d · 24 weeksAs given in this study (human).
Measurements
ucOC change, mean
1185%
PTH-treated group
ucOC change, SD
814.4%
PTH-treated group
ucOC change, mean
69.3%
placebo group
ucOC change, SD
79.4%
placebo group
Source sentences
Summary
ucOC increased by 1185.0 ± 814.4% (mean ± SD) in the PTH-treated group and by 69.3 ± 79.4% in the placebo group (P < 10(-50)).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
Report a problemFND-2595522601
02HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism, body weight decreased 1.1 ± 4.0% with PTH versus a placebo increase of 0.8 ± 2.5% (P = .04).
In plain wordsIn hypoparathyroidism, PTH reduced body weight compared with placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseBody weight
Study
n = 58
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
100 μg/d · 24 weeksAs given in this study (human).
Measurements
Body weight change, mean
−1.1%
PTH-treated group
Body weight change, SD
4%
PTH-treated group
Body weight change, mean
0.8%
placebo group
Body weight change, SD
2.5%
placebo group
Source sentences
Summary
In addition, body weight decreased by 1.1 ± 4.0% in the treatment group and increased 0.8 ± 2.5% in the placebo group (P = .04).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
Report a problemFND-2595522602
03HumanRandomized controlled trialSafety outcome
In hypoparathyroidism, hypercalcemic episodes averaged 3.7 ± 2.9 per patient with PTH versus 0.2 ± 0.6 with placebo (P < .001).
In plain wordsIn hypoparathyroidism, PTH increased hypercalcemic episodes compared with placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseHypercalcemic episodes per patient
Study
n = 58
Comparator
Placebo
Outcome group
Adverse events · Endocrine and hormones
Studied dose
100 μg/d · 24 weeksAs given in this study (human).
Measurements
Hypercalcemic episodes per patient, mean
3.7 episodes
PTH-treated group
Hypercalcemic episodes per patient, SD
2.9 episodes
PTH-treated group
Hypercalcemic episodes per patient, mean
0.2 episodes
placebo group
Hypercalcemic episodes per patient, SD
0.6 episodes
placebo group
Source sentences
Summary
In addition, the number of hypercalcemic episodes per patient was 3.7 ± 2.9 (mean ± SD) in the PTH-treated group but only 0.2 ± 0.6 in the placebo group (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
Report a problemFND-2595522604
04HumanNon-randomized trialEfficacy outcome
In the hypoparathyroidism PTH trial, glucose, adiponectin, leptin, insulin resistance, total body fat mass, and truncal fat did not change significantly.
In plain wordsIn the hypoparathyroidism PTH trial, glucose, adiponectin, leptin, insulin resistance, total body fat mass, and trunk fat did not change significantly.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeGlucose, adipokines, insulin resistance, and body fat
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
100 μg/d · 24 weeksAs given in this study (human).
Source sentences
Summary
Glucose, adiponectin, leptin, homeostasis model of assessment for insulin resistance, total body fat mass, or truncal fat did not change significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
Report a problemFND-2595522603

Studies that did not test the peptide alone3

In this study, PTH 1-84 (parathyroid hormone) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking PTH 1-84 (parathyroid hormone).

05HumanNot a test of PTH 1-84 (parathyroid hormone) aloneObservational studyMechanism
In the hypoparathyroidism PTH trial, ucOC change correlated negatively with body weight change (P = .004).
In plain wordsIn the hypoparathyroidism PTH trial, increased ucOC was linked to reduced body weight.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseucOC change association with weight change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Moreover, there was a significant and negative correlation between the change in ucOC and change in body weight (P = .004)
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
In this study, PTH 1-84 (parathyroid hormone) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PTH 1-84 (parathyroid hormone).
Report a problemFND-2595522605
06HumanNot a test of PTH 1-84 (parathyroid hormone) aloneObservational studyMechanism
In the hypoparathyroidism PTH trial, ucOC change correlated negatively with total body fat mass change (P = .03).
In plain wordsIn the hypoparathyroidism PTH trial, increased ucOC was linked to reduced total body fat mass.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseucOC change association with fat mass change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Moreover, there was a significant and negative correlation between the change in ucOC and change in body weight (P = .004) or change in total body fat mass (P = .03),
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
In this study, PTH 1-84 (parathyroid hormone) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PTH 1-84 (parathyroid hormone).
Report a problemFND-2595522606
07HumanNot a test of PTH 1-84 (parathyroid hormone) aloneObservational studyMechanism
In the hypoparathyroidism PTH trial, hypercalcemic episodes correlated negatively but nonsignificantly with percentage weight change (r = -0.32; P = .1).
In plain wordsIn the hypoparathyroidism PTH trial, more hypercalcemic episodes had a nonsignificant link to lower weight change.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseHypercalcemia association with weight change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Correlation, hypercalcemic episodes vs percentage weight change
−0.32 r
Hypoparathyroidism trial
Source sentences
Summary
a negative but nonsignificant correlation between the number of hypercalcemic episodes and percentage change in body weight (r = -0.32; P = .1).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week randomized, placebo-controlled trial.
Summary · context
Sixty-two patients aged 31-78 years with hypoparathyroidism, of which 58 completed the trial.Intervention100 μg/d of PTH (1-84).
In this study, PTH 1-84 (parathyroid hormone) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking PTH 1-84 (parathyroid hormone).
Report a problemFND-2595522607